Ding Y, Zhou YY, Chen H, Geng DD, Wu DY, Hong J, et al
10.3390/nu12061879 Nutrients
Large-scale cardiovascular outcome trials have demonstrated that certain GLP-1 agonists, including liraglutide, semaglutide, and dulaglutide, reduce the risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Bo Yang is the editorial board member of the journal and was not involved in the peer review or the decision making of the article
Schoors, S
This balance is essential to uphold cellular function and viability, and its disruption links to devastating human diseases